Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
story of the week
Published in Oncology and
1 other channel

Journal Scan / Research · September 21, 2022

Rezvilutamide vs Bicalutamide Plus ADT in Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Praful Ravi MB BChir, MRCP

The Lancet Oncology
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Lancet Oncol 2022 Sep 05;[EPub Ahead of Print], W Gu, W Han, H Luo, F Zhou, D He, L Ma, H Guo, C Liang, T Chong, J Jiang, Z Chen, Y Wang, Q Zou, Y Tian, J Xiao, J Huang, S Zhu, Q Dong, X Zhang, H Li, X Yang, C Chen, J Li, C Jin, X Zhang, D Ye

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated